English French German Italian Portuguese Russian Spanish

Klinikum der Universität München, Friedrich-Baur-Institute at the Department of Neurology

Klinikum der Universität München
Friedrich-Baur-Institute at the Department of Neurology

Prof. Thomas Klopstock & Dr. Ivan Karin
Ziemssenstr. 1a
80336 Munich, Germany
Phone: (+49) 089-44005-7421
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: http://www.baur-institut.de/

Klinikum der Universität München (KUM) is the maximal level hospital at the Ludwig-Maximilians University (LMU) München. It has 2400 beds providing medical care for 500.000 patients per year, as well as education for 5.000 medical students. It comprises 45 departments/institutes with 120 academic chairs and 10.000 staff members (1.700 physicians). The Medical Faculty has six main research topics officially defined: neuroscience, molecular biomedicine, oncology, inflammation/infection, regenerative medicine, medicine and society. The Friedrich-Baur-Institute (FBI) is part of the Department of Neurology and has a strong focus on neuromuscular, neurogenetic and mitochondrial disorders. It has been funded as a foundation since 1956 and is continuously receiving 450.000 € donations per year for research, therapy and health care in neuromuscular diseases. With its 70 staff members (17 physicians), FBI provides medical care for 4.000 patients per year and processes 600 muscle biopsies per year. Both BMBF-funded German networks on rare diseases that are coordinated by KUM are located at the Friedrich-Baur-Institute, network for muscle dystrophies (MD-NET) and network for mitochondrial diseases (mitoNET).


Prof. Thomas Klopstock has been working clinically and scientifically on mitochondrial and other neurogenetic diseases for 16 years. He runs an outpatient clinic for neurogenetic disorders, and is the Principal Coordinator of the German network for mitochondrial disorders (mitoNET). Moreover, he is head of a diagnostic neurogenetics lab and a molecular research lab at KUM. He has extensive experience as Investigator and Principal Investigator in both investigator-driven and industry-driven clinical trials in mitochondrial diseases, Friedreich ataxia and Parkinson disease. With regard to NBIA, he currently cares for patients with PKAN and other forms of NBIA.

The Technische Universität München (TUM) has earned a high international reputation that is apparent from research collaborations with more than 140 partner Universities, and its involvement in about 150 FP6 and currently (February 2010) more than 120 FP7 projects. Klinikum rechts der Isar (TUM-MED) is the university hospital of TUM. It is a renowned center for patient care, medical research, and teaching of medicine. It is treating some 40,000 in-house patients and 170,000 out-patients yearly.

The TUM-MED Institute of Human Genetics (head: Prof. Thomas Meitinger) with its joint institute at Helmholtz Zentrum München provides a powerful infrastructure for genomic research including platforms for next generation sequencing), genome wide analysis, metabolomics and computing infrastructure offering a wide range of technologies for systematic molecular research in human populations and model organisms. The institute has long-term experience with disease based biobanking. The Mitochondrial Disorder Group (head Dr. Holger Prokisch) explores genetic variation in both rare and common disorders with a functional focus on mitochondria-related disease mechanisms.

Klaus A. Kuhn, FACMI, is Full Professor of Medical Informatics at TUM and Director of the Institute of Med. Biometry and Epidemiology at TUM-MED. He is a faculty member of both the medical and the computer science faculty at TUM, a Fellow of the American College of Med. Informatics, and Vice President of the German Assoc. for Med. Informatics, Biometry, and Epidemiology. He is leading the projects “Data Integration System” and “IT for Biobanking” in the Munich Biotech Cluster M4 which receives significant funding as part of the Federal Government’s High-Tech Strategy.